Janssen has revealed that its androgen receptor (AR) inhibitor Erleada (apalutamide), in combination with androgen deprivation therapy (ADT), has been performing well in ongoing clinical studies investigating its efficacy in the treatment of metastatic castration-sensitive prostate cancer (mCSPC).
Things are going well enough, in fact, that the company announced it is to unblind the Phase 3 study, allowing patinets in the placebo plus ADT group to cross over to receive treatment in the Erleada plus ADT group.
![Design thinking als contentmarketeer inzetten [voorbeelden & tips]](https://www.pharmamarketeer.nl/wp-content/uploads/2024/11/business-team-working-in-a-start-up-office-2023-11-27-05-22-22-utc-1-80x60.jpg)
